Short Interest in Genprex, Inc. (NASDAQ:GNPX) Declines By 39.2%

Genprex, Inc. (NASDAQ:GNPX) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 50,600 shares, a drop of 39.2% from the June 15th total of 83,200 shares. Currently, 2.5% of the company’s stock are sold short. Based on an average daily volume of 100,600 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Genprex in a research report on Wednesday, May 15th.

Genprex Stock Up 4.3 %

Shares of NASDAQ GNPX traded up $0.08 during midday trading on Friday, reaching $1.92. 18,236 shares of the company’s stock were exchanged, compared to its average volume of 89,021. Genprex has a 52-week low of $1.77 and a 52-week high of $42.00. The business’s fifty day moving average price is $2.28 and its two-hundred day moving average price is $4.19.

Genprex (NASDAQ:GNPX) last announced its earnings results on Wednesday, May 15th. The company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($1.15). As a group, equities analysts anticipate that Genprex will post -5.7 earnings per share for the current fiscal year.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.